Intrigued by the idea of better dissecting the features accounting for long-lasting CAR T cell anti-tumor responses, we retrospectively correlated CAR T cell features with therapeutic outcomes in vivo, collecting all data from leukemia-bearing mice treated with CD19 CAR T cells derived from HDs, B-ALL and PDAC patients. The gene discussed is CD19; the disease is neoplasm.